U.S. pharma large copyright scrapped two experimental weight loss tablets very last calendar year—a when-daily tablet, lotiglipron, as a consequence of elevated liver enzymes and a twice-day-to-day pill, danuglipron, as a consequence of sturdy Unwanted side effects—but CEO Albert Bou